These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17602094)

  • 1. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
    Di Lorenzo L
    J Clin Oncol; 2007 Jul; 25(19):2858-9; author reply 2859-61. PubMed ID: 17602094
    [No Abstract]   [Full Text] [Related]  

  • 2. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
    Christensen JG
    Ann Oncol; 2007 Sep; 18 Suppl 10():x3-10. PubMed ID: 17761721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib malate.
    Izzedine H; Buhaescu I; Rixe O; Deray G
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):357-64. PubMed ID: 17136543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
    Bavcar S; Argyle DJ
    Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.
    Scagliotti GV
    Ann Oncol; 2007 Sep; 18 Suppl 10():x32-41. PubMed ID: 17761722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
    de Brito LR; Batey MA; Zhao Y; Squires MS; Maitland H; Leung HY; Hall AG; Jackson G; Newell DR; Irving JA
    Leuk Res; 2011 Sep; 35(9):1233-40. PubMed ID: 21316102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib malate for the treatment of solid tumours: a review of current clinical data.
    Motzer RJ; Hoosen S; Bello CL; Christensen JG
    Expert Opin Investig Drugs; 2006 May; 15(5):553-61. PubMed ID: 16634693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
    Dudek AZ; Murthaiah PK; Franklin M; Truskinovsky AM
    Acta Oncol; 2010; 49(1):101-4. PubMed ID: 19412810
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lung cancer: molecular targeting therapy].
    Kobayashi K
    Nihon Kokyuki Gakkai Zasshi; 2004 May; 42(5):371-7. PubMed ID: 15168452
    [No Abstract]   [Full Text] [Related]  

  • 11. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 12. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
    Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F
    Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
    Addeo R; Caraglia M
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):139-42. PubMed ID: 21342029
    [No Abstract]   [Full Text] [Related]  

  • 15. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
    Hu-Lowe D; Brega N; Patyna S
    Mol Cancer Ther; 2011 Nov; 10(11):2015. PubMed ID: 22072801
    [No Abstract]   [Full Text] [Related]  

  • 17. Artificial signal transduction therapy: a futuristic approach to disease treatment.
    Peri-Naor R; Motiei L; Margulies D
    Future Med Chem; 2015; 7(16):2091-3. PubMed ID: 26510968
    [No Abstract]   [Full Text] [Related]  

  • 18. SU11248 and AG013736: current data and future trials in renal cell carcinoma.
    Rini BI
    Clin Genitourin Cancer; 2005 Dec; 4(3):175-80. PubMed ID: 16425985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacia's SU5416 not effective.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):5. PubMed ID: 12113066
    [No Abstract]   [Full Text] [Related]  

  • 20. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.